<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03462498</url>
  </required_header>
  <id_info>
    <org_study_id>C1348</org_study_id>
    <nct_id>NCT03462498</nct_id>
  </id_info>
  <brief_title>ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS</brief_title>
  <acronym>STOPDAPT-2 ACS</acronym>
  <official_title>Study to Evaluate the Safety of Reducing Dual Antiplatelet Therapy (DAPT) Duration to 1 Month for Patients With Acute Coronary Syndrome (ACS) After Implantation of Everolimus-eluting Cobalt-chromium Stent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyoto University, Graduate School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyoto University, Graduate School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of reducing dual antiplatelet therapy&#xD;
      (DAPT) duration to 1 month after implantation of the everolimus-eluting cobalt-chromium stent&#xD;
      (CoCr-EES) under the setting of acute coronary syndrome (ACS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug-eluting stents (DESs) are currently used in the majority of percutaneous coronary&#xD;
      intervention (PCI) procedures. On the other hand, the problems of the first-generation DES&#xD;
      (late adverse events, such as very late stent thrombosis) have been pointed out. Dual&#xD;
      antiplatelet therapy (DAPT) has become a standard regimen after DES implantation and for fear&#xD;
      of very late stent thrombosis, DAPT is frequently performed for 1 year or longer in clinical&#xD;
      practice. Especially guidelines recommend 1-year DAPT for patients with acute coronary&#xD;
      syndrome (ACS), though its rational is based on the study more than 15 years old. However,&#xD;
      serious hemorrhagic complications associated with prolonged DAPT duration can bring&#xD;
      disadvantages to patients, and it is extremely important to clarify an optimal DAPT duration&#xD;
      after DES procedure. Currently, 1-month DAPT regimen after bare metal stent (BMS)&#xD;
      implantation is commonly used in clinical practice, producing no major problems. Based on a&#xD;
      meta-analysis of recent clinical studies, it has also been reported that the use of&#xD;
      Cobalt-Chromium Everolimus-Eluting Stent (CoCr-EES) reduces the risk of early stent&#xD;
      thrombosis by half compared to the use of BMS. There is no necessity to extend antiplatelet&#xD;
      therapy after CoCr-EES implantation longer than after BMS implantation, and it is considered&#xD;
      possible to use the same 1-month DAPT duration as after BMS implantation. The investigators&#xD;
      already planned and started a multicenter, randomized, open-label, controlled study, in which&#xD;
      the subjects who have undergone CoCr-EES procedure will be divided into the 1-month DAPT and&#xD;
      clopidogrel monotherapy group and the 12-month DAPT and aspirin monotherapy group&#xD;
      (STOPDAPT-2; NCT02619760), where primary endpoint is the incidence of composite events&#xD;
      including cardiovascular death, myocardial infarction, stent thrombosis, stroke, and bleeding&#xD;
      defined by TIMI major or minor bleeding. In STOPDAPT-2, the non-inferiority about primary&#xD;
      endpoint of 1-month DAPT group will be evaluated at 12 months after index procedure and&#xD;
      secondarily, the superiority about primary endpoint of 1-month DAPT group will be evaluated&#xD;
      at 5 years after index procedure. The proportion of patients with ACS is about 30-40% in&#xD;
      STOPDAPT-2 and the power is insufficient to evaluate the safety and efficacy of 1-month DAPT&#xD;
      regimen specifically for patients with ACS. Therefore the investigators planned the current&#xD;
      study to enroll patients of ACS with the same protocol as STOPDAPT-2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite event of cardiovascular death/myocardial infarction/definite stent thrombosis/stroke/bleeding defined as major or minor under the definition of Thrombolysis in Myocardial Infarction (TIMI) Study group</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite event of cardiovascular death/myocardial infarction/definite stent thrombosis/stroke/bleeding defined as major or minor under the definition of Thrombolysis in Myocardial Infarction (TIMI) Study group</measure>
    <time_frame>60 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite event of cardiovascular death/myocardial infarction/definite stent thrombosis/stroke</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite event of cardiovascular death/myocardial infarction/definite stent thrombosis/stroke</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding defined as major or minor under the definition of Thrombolysis in Myocardial Infarction (TIMI) Study group</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding defined as major or minor under the definition of Thrombolysis in Myocardial Infarction (TIMI) Study group</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Upper gastrointestinal endoscopic examination or treatment</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite event of all-cause death/myocardial infarction</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite event of all-cause death/myocardial infarction</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite event of cardiovascular death/myocardial infarction</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite event of cardiovascular death/myocardial infarction</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite stent thrombosis</measure>
    <time_frame>12 months</time_frame>
    <description>Academic Research Consortium definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite stent thrombosis</measure>
    <time_frame>60 months</time_frame>
    <description>Academic Research Consortium definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac event</measure>
    <time_frame>12 months</time_frame>
    <description>Composite of cardiac death, myocardial infarction, and clinically-driven TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac event</measure>
    <time_frame>60 months</time_frame>
    <description>Composite of cardiac death, myocardial infarction, and clinically-driven TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically-driven target lesion revascularization</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically-driven target lesion revascularization</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non target lesion revascularization</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non target lesion revascularization</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary artery bypass graft</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary artery bypass graft</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any coronary revascularization</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any coronary revascularization</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding complications</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding complications</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal bleeding</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal bleeding</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal complaints requiring upper gastrointestinal endoscopy</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal complaints requiring upper gastrointestinal endoscopy</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3008</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Acute Myocardial Infarction</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <condition>Platelet Aggregation Inhibitors</condition>
  <arm_group>
    <arm_group_label>1-month DAPT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists and clopidogrel monotherapy for 59 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12-month DAPT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists; 11-month DAPT composed of aspirin and clopidogrel and aspirin monotherapy for 48 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1-months DAPT</intervention_name>
    <description>1-month DAPT followed by 59-month monotherapy</description>
    <arm_group_label>1-month DAPT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>12-month DAPT</intervention_name>
    <description>12-month DAPT followed by 48-month monotherapy</description>
    <arm_group_label>12-month DAPT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients received percutaneous coronary intervention with cobalt-chromium&#xD;
             everolimus-eluting stent under the setting of acute coronary syndrome&#xD;
&#xD;
          -  Patients who are capable of oral dual antiplatelet therapy consisting of aspirin and&#xD;
             P2Y12 receptor antagonist&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients requiring oral anticoagulants&#xD;
&#xD;
          -  Patients with medical history of intracranial hemorrhage&#xD;
&#xD;
          -  Patients who have experienced serious complications (myocardial infarction, stroke,&#xD;
             and major bleeding) during hospital stay after percutaneous coronary intervention&#xD;
&#xD;
          -  Patients with drug eluting stents other than Cobalt chromium everolimus eluting stents&#xD;
             implanted at the time of enrollment&#xD;
&#xD;
          -  Patients confirmed to have no tolerability to clopidogrel before enrollment&#xD;
&#xD;
          -  Patients requiring continuous administration of antiplatelet drugs other than aspirin&#xD;
             and P2Y12 receptor antagonists at the time of enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takeshi Kimura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kyoto University Graduate School of Medicine</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 6, 2018</study_first_submitted>
  <study_first_submitted_qc>March 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2018</study_first_posted>
  <last_update_submitted>September 4, 2021</last_update_submitted>
  <last_update_submitted_qc>September 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyoto University, Graduate School of Medicine</investigator_affiliation>
    <investigator_full_name>Takeshi Morimoto</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Acute Coronary Syndrome</keyword>
  <keyword>Acute Myocardial Infarction</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>Platelet Aggregation Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

